On Demand Education

Integrating new technology into the management of non-dysplastic Barrett’s esophagus patients

Castle Biosciences hosted a case-based panel discussion at DDW 2023 highlighting how TissueCypher aids in the management of non-dysplastic Barrett’s esophagus patients.

Lipham J, Muthusamy R, Khara H

Individualized Risk Prediction in Barrett’s Esophagus

Jul 2016

Medical Laboratory Observer

Aaron DeWard

A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett’s Esophagus

Feb 2017

Rebecca J. Critchley-Thorne

A Tissue Systems Pathology Assay for High-Risk Barrett’s Esophagus

May 2016

Rebecca J. Critchley-Thorne

A Cost-Effectiveness Analysis of an Adenocarcinoma Risk Prediction Multi-Biomarker Assay for Patients with Barrett’s Esophagus

Oct 2019

Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients with Barrett’s Esophagus

Jun 2020

A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.

Jon M Davison

Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Non-Dysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis

Oct 2020

Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.

Nicola F Frei

Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies

Feb 2022

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Iyer PG, Codipilly DC, Chandar AK, Agarwal S, Wang KK, Leggett CL, Latuche LR, Schulte PJ

Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar

A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.

Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy Northwestern University, David Diehl, MD, FACP, FASGE Director of Interventional Endoscopy Geisinger Health System, Prasad G. Iyer, MD, MS, FASGE, FACG, Gastroenterologist, Mayo Clinic

Risk Stratification and Management of Dysplastic Barrett’s Esophagus

Jun 2022

Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.

TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*

Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).

Nicola Frei, Doctor of Medicine, Amsterdam UMC

Barrett’s Esophagus Panel: Establishing Individual Patient Risk for Progression to Esophageal Cancer

Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.

Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy Northwestern University. Rhonda Souza, MD,Co-Director, Baylor Scott & White Health, Vani Konda, MD Medical Director Baylor Scott & White Health